Secondary Logo

Journal Logo

The role of hyperuricemia in vascular disorders

Edwards, N Lawrence

Current Opinion in Rheumatology: March 2009 - Volume 21 - Issue 2 - p 132–137
doi: 10.1097/BOR.0b013e3283257b96
Crystal deposition diseases: Edited by John Sundy
Free

Purpose of review The role of uric acid as a mediator of vascular damage is not a new idea but has only recently gained widespread acceptance. Uric acid has previously been viewed as a benign solute in serum until it exceeds its saturation level. Others have viewed it as an important antioxidant. These opinions have given way to strong epidemiologic evidence that uric acid elevation may damage endothelial cells and cause significant medical problems.

Recent findings The comorbidities associated with gout include hypertension, renal failure, obesity and diabetes. Multiple large epidemiologic studies cited in this review show that uric acid itself may play an important role in initiating the vascular endothelial dysfunction associated with this cluster of medical problems and ultimately lead to stroke, coronary artery disease and chronic kidney disease. These studies are supported by experiments in animals demonstrating how uric acid can gain entrance into cells and function as a ‘pro-oxidant’.

Summary Uric acid has been long recognized as the cause of gouty arthritis and kidney stones. There is mounting evidence that it may also have an important role in the development of vascular conditions such as coronary heart disease, stroke and kidney disease. These findings have important implications for the way we view asymptomatic hyperuricemia and for future therapeutic interventions.

Department of Medicine, Division of Rheumatology, University of Florida, Gainesville, Florida, USA

Correspondence to N. Lawrence Edwards, MD, FACP, FACR, Professor of Medicine, Department of Medicine, Division of Rheumatology, University of Florida, Gainesville, FL 32610-0221, USA Tel: +1 352 265 0239; fax: +1 352 265 1107; e-mail: edwarnl@medicine.ufl.edu

Back to Top | Article Outline

Introduction

Hyperuricemia is a metabolic problem that has become increasingly common worldwide over the past several decades. The association of hyperuricemia and gout with other medical conditions such as hypertension, chronic kidney disease, dyslipidemias and cardiovascular disease has been recognized for over 100 years [1••]. Until the past decade, the association between uric acid and these serious medical problems was considered to be a simple clustering of conditions that had similar risk factors, including lifestyles that were heavy on excesses of food and drink and light on exercise. Although a direct causal role of uric acid was suggested by Mohamed in the earliest description of essential hypertension [2], no scientific hypothesis for this association was put forward until recently. A new understanding of how uric acid is transported in and out of cells, along with animal studies of the vascular effects of soluble uric acid and a plethora of epidemiologic trials demonstrating serum urate to be an independent risk factor in the development of hypertension, cardiovascular disease, chronic kidney disease, stroke and possibly the metabolic syndrome have led to a reappraisal of the role of uric acid in human health and disease [3].

Back to Top | Article Outline

Evolutionary origin of hyperuricemia

The causes of hyperuricemia in humans are usually divided between overproduction and underexcretion of uric acid. In reality, all humans are hyperuricemic compared with all other mammals except for the great apes. This is caused by a series of genetic mutations to the uricase gene and the promotor between 15 and 20 million years ago [4]. Most mammals with a functioning uricase gene have serum urate levels in the 1–2 mg/dl range. Nonhuman primates and primitive humans not exposed to western diets have serum urates in the 2–4 mg/dl range compared with serum urates of 4–10 mg/dl in modern humans on a western diet [5•]. Several theories have been proposed to explain how this enzymatic mutation conveyed a survival advantage to the species. These include uric acid's potential roles as a neurostimulant, an antioxidant or a mechanism for raising blood pressure. The structural similarity between uric acid and caffeine and other neurostimulatory molecules has raised the possibility that this mutation in uricase led to some increase in alertness and intelligence that would have offered evolutionary advantage [6].

Another hypothesis of selective advantage of having an elevated serum urate level is that uric acid functions as an antioxidant, which partially made up for the loss of ability to endogenously produce vitamin C [7]. Many mammals lost this ability approximately 15–30 million years prior to the loss of uricase enzyme [5•]. This mutation involved the final enzyme in the pathway of vitamin C biosynthesis, L-gulonolactoneoxidase. Uric acid, like vitamin C, functions as an antioxidant and is thought to play a key role in the protection against oxidative stress by blocking lipid peroxidation, DNA damage and alkylation and membrane injury [5•,8–10].

The final hypothesis of how an elevated uric acid may impart a survival advantage to our species has to do with its effect on blood pressure. In a hypothesis, a higher blood pressure would allow for greater cerebral blood perfusion when our ancestors assumed an upright position [11]. The survival advantage offered by a higher uric acid level during the mid-Miocene period when dietary sources of vitamin C and sodium were low have been lost in modern man. It is now very possible that the survival advantages offered to our ancestors are now the sources of disease in modern man [5•].

Back to Top | Article Outline

Vascular comorbidities associated with hyperuricemia

The prototypic picture of a gouty patient is that of an obese, middle-aged man with a propensity for overindulgence in food and alcoholic beverages. This person is also commonly afflicted with hypertension, kidney disease, diabetes mellitus and a predilection for other vascular problems such as coronary artery disease and vascular stroke [12]. Of course, not all gouty patients fit the morphometric description of this prototype or suffer the vascular consequences listed above. What is true of all gouty patients, however, is that they have a history of hyperuricemia. The incidence of hyperuricemia in the world's population has steadily increased over the past 40 years and varies from country to country. Data from recent epidemiologic studies reveal that between 10 and 20% of most western populations are hyperuricemic, defined as a serum urate equal to or greater than 7.0 mg/dl. The likelihood of individuals with hyperuricemia developing gout depends primarily on the degree of uric acid elevation. Patients with a serum urate of greater than 9 mg/dl have an accumulated incidence of experiencing gout in 5 years of 22% [13]. This percentage declines as serum urate levels decline.

Hyperuricemia is linked to a wide spectrum of metabolic and vascular conditions, including hypertension, renal disease, metabolic syndrome and both coronary and cerebral vascular disease [14]. It has also been well documented that uric acid levels correlate with traditional vascular risk factors such as older age, male sex, obesity, dyslipidemia and insulin resistance [15]. This complex relationship between hyperuricemia and numerous vascular risk factors has been interpreted by many to show that the relationship between uric acid and vascular disease may, in fact, be epiphenomenal rather than causal.

Back to Top | Article Outline

The argument against uric acid being an independent risk factor for vascular disease

Over the past 25 years, many large and well designed studies have focused on the relationship between serum urate and the likelihood of developing vascular diseases. Several of these studies have concluded that uric acid is a ‘predictive marker’ for developing cerebrovascular disease [16–19], renal disease [20,21] or hypertension [22,23]. The types of multivariate analyses used to distinguish dependent risk factors from independent risk factors vary between these studies. Inadequate control or weighing of known risk factors for vascular disease is frequently cited for inconsistent conclusions by these studies [1••,24•]. The primary argument against a causal role for uric acid is that changes in the kidneys caused by hypertension and the drugs used to treat hypertension both lead to hyperuricemia rather than the other way around. From this viewpoint, hyperuricemia is epiphenomenal to hypertension. By extension, the subsequent tissue damage caused by hypertension leading to cardiovascular disease, chronic kidney disease and stroke makes uric acid epiphenomenal to these medical conditions.

Back to Top | Article Outline

Reasons for reappraisal

The debate about uric acid being a direct cause of vascular disease or tissue damage is epitomized in the publications about uric acid-associated kidney disease over the past 50 years. On the basis of a very high incidence (79–99%) of interstitial and vascular disease in autopsied kidneys from gouty patients, Talbott coined the term ‘gouty nephropathy’ to describe this condition [24•,25]. This concept was extended by Klinenberg et al. in 1975 [26] when they described similar renal involvement in patients with asymptomatic hyperuricemia. This was followed by two decades of opposition to the idea that noncrystalized uric acid could be responsible for tissue damage or that even localized deposits of urate crystals could account for generalized renal dysfunction. This led to a rejection by many in the nephrology community that uric acid had a direct toxic effect to kidneys other than that associated with kidney stones or postchemotherapy acute urate nephropathy. There was no perceived model or mechanism by which soluble uric acid could inflict damage to endothelial cells or other vascular tissues. Therefore, all damage observed with hyperuricemia and gout was assumed to be caused by the associated hypertension [25].

Beginning in the mid to late 1990s, several studies in a rat model of mild hyperuricemia showed that renal microvascular changes would develop when hyperuricemia was induced. Direct effects of uric acid on endothelial and vascular smooth muscle cells suggested that uric acid could cause microvascular damage independent of hypertension or the presence of urate crystals [27]. Further studies went on to show that hyperuricemic rats exhibited an increase in juxtaglomerular renin and a decrease in macula densa neuronal nitric oxide synthetase [28]. Despite these observations in the animal model, there continued to be skepticism about a direct role for uric acid in endothelial dysfunction, as it was not clear how a compound generally viewed to be an extracellular solute could exert its effect intracellularly. Our understanding of specific urate transport was greatly enhanced in 2002 with the identification of the renal urate-anion exchange transporter, URAT-1 [29]. The action of this specific uric acid transporter is now felt to be primarily responsible for renal tubular reabsorption of uric acid in the proximal convoluted tubule and regulation of blood urate levels. The expression of URAT-1 on cell surface is restricted to the renal tubular epithelium but expression has recently been demonstrated in endothelial cells and vascular smooth muscle cells of afferent renal arterioles being one of the few sites other than renal tubular epithelium [30]. This observation made a direct intracellular function of uric acid at least feasible.

In addition to these molecular discoveries and animal models that support a direct metabolic effect of soluble urate, many recent publications have revealed hyperuricemia to predict the development of hypertension [31–34,35••,36–38], diabetes [39,40] and obesity [41•,42•,43]. Well designed and controlled studies have also shown uric acid to be an independent risk factor for both cardiovascular disease [44–48] and kidney disease [21,22,48].

At the very heart of the controversy regarding the role of uric acid in vascular disease is the relationship between hyperuricemia and hypertension. As the argument could always be made that any vascular changes in the heart, brain or kidney might be caused by hypertension, it was important to establish a direct causal relationship between hyperuricemia and hypertension. Going beyond the epidemiologic studies, Feig et al.[49••] have recently demonstrated that lowering uric acid in adolescents with newly diagnosed essential hypertension results in a reduction in blood pressure. This observation uniquely supports the hypothesis that soluble uric acid may be an important etiologic factor in vascular disease.

Back to Top | Article Outline

Uric acid and hypertension

The strong association between hypertension and hyperuricemia has been recognized for more than a century. Studies from the 1950s and 1960s showed the prevalence of hyperuricemia in hypertensive patients to be between 20 and 40% [50]. The prevalence of hypertension among gouty patients is between 25 and 50%. In 1972, Kahn et al.[51] found that a rising level of serum urate is an independent risk factor for hypertension. The following year, Klein et al.[52] demonstrated a linear relationship between serum urate levels and systolic blood pressure in both black and white patients. Seven large epidemiologic studies [31,35••,36,38,39,41•,53] published over the past 7 years have found that serum urate levels predict the later development of hypertension. The two most recent of these studies are the Normative Aging Study by Perlstein et al.[53] and the evaluation of the Multiple Risk Factor Intervention Trial (MRFIT) Study by Krishnan et al.[35••].

The Normative Aging Study [53] showed that the serum urate level independently predicted the development of hypertension when using age-adjusted and multivariate models that included body mass, abdominal girth, alcohol use, serum lipids, plasma glucose and smoking status. It also took into account renal function and insulin resistance. In this longitudinal cohort study of healthy adult men from the Boston area, the risk of developing hypertension was linear in its relationship to serum urate levels.

A recent analysis of the MRFIT data [35••] investigated the risk of developing hypertension over a 6-year follow-up period in men who were normotensive at the outset but had baseline hyperuricemia. These patients had no evidence of glucose intolerance or the metabolic syndrome. Again, in this model, adjustments were made for the effect of serum creatinine, BMI, age, blood pressure, proteinuria, tobacco and alcohol use as well as serum lipids. The results of this study showed that normotensive men with a baseline hyperuricemia had an 80% excess risk for developing hypertension compared with those who did not have hyperuricemia.

The preponderance of recent epidemiologic studies looking at hypertension and hyperuricemia has concluded that uric acid is an independent risk for the development of hypertension. But the frequent clinical observation that adult patients taking allopurinol do not have consistent improvement in their hypertension has made many question this direct effect. The recently published studies by Feig et al.[49••] demonstrating that hypertension in adolescents could be controlled by urate lowering may provide an explanation for this paradox. Relying on what was seen with the rat models of hyperuricemia, this group of investigators suggest that essential hypertension in its earliest stages is uric acid-sensitive but sodium-insensitive. With persistence of hypertension over a period of time, structural changes occur within the kidney and essential hypertension becomes uric acid-insensitive and sodium-sensitive. This explanation would fit the observation that uric acid levels are associated with hypertension but lowering uric acid in adults does not have a beneficial effect.

Back to Top | Article Outline

Hyperuricemia and chronic kidney disease

Two large prospective studies from Japan have recently examined the relationship between serum urate levels and the development of kidney disease. Using multivariate analysis to adjust for age, blood pressure, BMI, proteinuria, hematocrit, hyperlipidemia, fasting glucose and creatinine, Iseki et al.[20] screened 48 177 Japanese adults and calculated the cumulative incidence of end-stage renal disease (ESRD) according to quartiles of baseline serum urate levels for each sex. The calculated incidence of ESRD per thousand screenees was 1.22 for men without hyperuricemia (less than 7.0 mg/dl) versus 4.64 for men with hyperuricemia (greater than or equal to 7.0 mg/dl). For women using a cut-off urate level of 6.0 mg/dl, the incidence of ESRD per thousand screenees was 0.87 for those with low urate levels versus 9.0 for those with higher urate levels.

Tomita et al.[21] investigated the relationship between serum urate levels and various health hazards in a prospective cohort study that followed 49 413 male Japanese railroad workers over an average 5.4 years. They found a strong association between serum urate levels and renal failure, even when adjusted for covariant effects. Patients having uric acid levels greater than 8.5 mg/dl demonstrated an eight-fold increase in risk of renal failure relative to patients with moderate urate levels (5.0–6.4 mg/dl).

Several studies [54–56] have shown that urate-lowering therapy in patients with renal insufficiency may in fact improve renal function or decrease the speed of deterioration in patients with chronic kidney disease.

Back to Top | Article Outline

Hyperuricemia and cardiovascular disease

Hyperuricemia has been demonstrated in multiple recent studies to be an independent risk factor for atherosclerotic disease in general and for coronary artery disease in particular [12]. In the National Health and Nutrition Examination Survey III (NHANESIII), over 16 000 patients were evaluated and uric acid levels in excess of 6 mg/dl were viewed to be an independent risk factor for coronary heart disease. In the same study, a serum urate level over 7 mg/dl was shown to be an independent risk factor for stroke [57]. In the Systolic Hypertension in the Elderly Program of 4372 patients [47], uric acid again was shown to be an independent risk factor for cardiovascular events overall. When comparing the lowest quartile of serum urate levels against the highest quartile, there was a 32% increase in cardiovascular events overall and this was even higher in white men. It was determined that an increase in serum urate of 1 mg/dl from baseline to 12 months was associated with a 72% increase in risk of cardiovascular event.

From multiple studies, it appears the relationship between uric acid and cardiovascular disease is quite strong and is especially pertinent in patients who are at high risk for heart disease and also in women. A mechanism for direct causal relationship between uric acid and cardiovascular events remains to be determined.

Back to Top | Article Outline

Hyperuricemia and the metabolic syndrome

The clinical association of diabetes and obesity with hyperuricemia and gout has been well recognized. Hyperuricemia associated with the metabolic syndrome has been attributed to insulin resistance and hyperinsulinemia in this disease. Insulin is known to reduce renal excretion of uric acid leading to the assumption that hyperuricemia is epiphenomenal in the metabolic syndrome. However, recent studies have shown that hyperuricemia precedes the development of obesity, diabetes and even hyperinsulinemia. In one study of nonobese patients who developed metabolic syndrome [58•], those with hyperuricemia were noted to be at a 10-fold increase in risk compared with those with normal uricemia.

When a large registry of gout patients was examined in both the UK and in Germany, the comorbidities most commonly found to be associated with gout were obesity in the UK and diabetes in Germany [41•]. There appears to be a direct linear association between these metabolic conditions and the degree of hyperuricemia.

Although the clinical evidence to establish a direct link between uric acid and the metabolic syndrome is relatively small compared with data demonstrating association with hypertension, kidney disease and heart disease, there is support in animal models of metabolic syndrome for a direct role of uric acid [43,59]. There is also some evidence suggesting that lowering serum urate levels can reverse features of the metabolic syndrome [43]. The question raised in these studies is whether the benefit seen with urate lowering is caused by the reduction in uric acid itself or if by inhibiting xanthine oxidase, the production of superoxide, hydrogen peroxide and hydroxoradicals is decreased resulting in endothelial dysfunction.

Back to Top | Article Outline

Conclusion

In this article, I have described a steadily growing literature on the association of hyperuricemia with several forms of vascular disease. The preponderance of data is now on the side that hyperuricemia is an independent risk factor for the development of hypertension, kidney disease, cardiovascular disease and stroke. Although mechanisms for a causal relationship between soluble uric acid and these various medical problems are not entirely clear, animal studies are providing some mechanistic insight. It is tempting for the clinician to view these data as an invitation to lower serum uric acid levels to decrease the risk of morbidity and mortality from vascular disease but a cautionary note should be made. Drugs that are currently available to lower serum urate levels, including allopurinol and probenecid, have side effects and this risk cannot justify their use in the treatment of asymptomatic hyperuricemia. I do believe that in the near future, cohorts of patients that are at unusual risk for these uric acid-associated vascular problems may be identified and this might shift the risk: benefit ratio in the direction of treatment.

Back to Top | Article Outline

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest

•• of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 192).

1•• Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359:1811–1821. Excellent review of the scientific studies supporting and refuting the role of uric acid in cardiovascular disease.
2 Mohamed FA. On chronic Bright's disease, and its essential symptoms. Lancet 1879; 1:399–401.
3 Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008; 75:S13–S16.
4 Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34:78–84.
5• Johnson RJ, Gaucher EA, Sautin YY, et al. The planetary biology of ascorbate and uric acid and their relationship with the epidemic of obesity and cardiovascular disease. Med Hypotheses 2008; 71:22–31. Recent review of uric acid's role as an antioxidant and pro-oxidant in human health and disease. It also reviews the evolutionary theories linking the loss of endogenous vitamin C production and the development of hyperuricemia.
6 Orowan E. The origin of man. Nature 1955; 175:683–684.
7 Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78:6858–6862.
8 Simie MG, Jovanovic SV. Antioxidation mechanisms of uric acid. J Am Chem Soc 1989; 111:5778–5782.
9 Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrate and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000; 376:333–337.
10 Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22:1402–1408.
11 Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40:355–360.
12 Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of myocardial infarction. Arthritis Rheum 2006; 54:2688–2696.
13 Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421–426.
14 Rich RW. Uric acid: is it a risk factor for cardiovascular disease? Am J Cardiol 2000; 85:1018–1021.
15 Rathman W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Ann Epidemiol 1998; 8:250–261.
16 Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 8:858–865.
17 Brand FN, McGee DL, Kannell WB, et al. Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985; 121:11–18.
18 Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: atherosclerosis risk in communities (ARIC) study. Ann Epidemiol 2000; 10:136–143.
19 Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78:147–153.
20 Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642–650.
21 Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000; 10:403–409.
22 Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the European Working Party on High Blood Pressure in the Elderly trial. Am J Med 1991; 90:50S–53S.
23 De Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213–2222.
24• Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18:287–292. This subset analysis of the Health Professionals Follow-up Study demonstrated that when adjustments were made for known hypertension risk factors, as well as for fasting insulin and serum lipids, there was no independent association between serum urate levels and the risk of incident hypertension in older men.
25 Talbott JH, Terplan KL. The kidney and gout. Med 1960; 39:405–465.
26 Klininberg JR, Kippen I, Bluestone R. Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron 1975; 14:88–98.
27 Beck L. Requiem for gouty nephropathy. Kidney Int 1986; 30:280–287.
28 Eng E, Veniant M, Floege J, et al. Renal proliferation and phoentypic changes in rats with two-kidney, one clip Goldblatt hypertension. Am J Hypertens 1994; 7:177–185.
29 Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38:1101–1106.
30 Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417:447–452.
31 Price KL, Sautin YY, Long DA, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006; 17:1791–1795.
32 Alper AB Jr, Chen W, Yau L, et al. Childhood uric acid predicts adult blood pressure: the Bogalusa Heart study. Hypertension 2005; 45:34–38.
33 Dyer AR, Liu K, Walsh M, et al. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. J Hum Hypertens 1999; 13:13–21.
34 Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: the Olivetti Heart study. J Hum Hypertens 1994; 8:677–681.
35•• Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49:298–303. This study uses a subset of men from the MRFIT database who did not have hypertension or the metabolic syndrome at baseline to demonstrate that hyperuricemia increases the risk of developing hypertension by 80% and is independent of other confounders.
36 Masuo K, Kawaguchi H, Mikami H. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42:474–480.
37 Mellen PB, Bleyer AJ, Erlinger, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 2006; 48:1037–1042.
38 Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27:835–841.
39 Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003; 18:523–530.
40 Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 2001; 19:1209–1215.
41• Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008; 67:960–966. This study examined the medical records of nearly 5 million patients in the UK and Germany and showed that patients with gout had a high frequency of comorbidities. The frequency of the comorbidities varied between the two countries with obesity being the highest in the UK and diabetes in Germany.
42• Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31:361–362. Using the database from the large Rotterdam Study, this study describes serum urate a strong, independent risk for the development of type 2 diabetes.
43 Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006; 290:F625–F631.
44 Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 2000; 283:2404–2410.
45 Liese AD, Hense H-W, Lowel H, et al. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg Cohort. Epidemiology 1999; 10:391–397.
46 Verdecchia P, Schillaci G, Reboldi GP, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA Study. Hypertension 2000; 36:1072–1078.
47 Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000; 18:1149–1154.
48 Wang J-G, Staessen JA, Fagard RH, et al. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37:1069–1074.
49•• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300:924–932. This short-term, crossover study demonstrates that allopurinol reduces blood pressure in adolescents with essential hypertension. This supports the hypothesized role of uric acid in the development of hypertension and vascular comorbidities.
50 Kinsey D, Walther R, Sise HS, et al. Incidence of hyperuricemia in 400 hypertensive patients. Circulation 1961; 24:972–976.
51 Kahn HA, Medalie JH, Neufeld HN, et al. The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 1972; 84:171–182.
52 Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationships to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Int Med 1973; 132:401–410.
53 Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension in the Normative Aging Study. Hypertension 2006; 48:1031–1036.
54 Sin Y, Leung K, Tong M, Kwan T. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47:51–59.
55 Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57:545–549.
56 Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982; 41:59–65.
57 Ward H. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352:670–671.
58• Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120:442–447. The direct relationship between hyperuricemia and the individual components of the metabolic syndrome has been reported. This large study using the NHANES III database is the first to show that the prevalence of the metabolic syndrome itself increases substantially with rising serum urate levels.
59 Hwang IS, Ho H, Hoffman RB, Reaves GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10:512–516.
Keywords:

asymptomatic hyperuricemia; chronic kidney disease; coronary artery disease; hypertension; pro-oxidant

© 2009 Lippincott Williams & Wilkins, Inc.